ReviewFrontiers in immunology2023

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.

Ricardo D Parrondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.